SELECXINE

본문 바로가기

Our Story | History | Leadership

Our Story

Selecxine is a biopharmaceutical development company specialized in the field of immunotherapeutics.

Selecxine strives to develop immunotherapeutics – a new paradigm of pharmaceuticals– through a specialized antibody development process, using an innovative platform technology of functional antibody screening and development.

We endeavor to improve the survival rate and quality of life of cancer patients by developing anti-cancer immunotherapeutics that selectively stimulate the immune cells. These agents act against tumor cells through the regulation of cytokine function, which plays a key role in the enter cell activities.

Based on our technology and expertise in the pharmacology and development field,
we aim to provide safe and efficient therapeutics and innovative solutions for
next-generation pharmaceuticals.

CEO, Selecxine Inc. Jun-Young Lee

History

Based on our unique technology, active research, development collaboration,
Selecxine is putting an effort into the development of effective immunotherapeutics to
improve the patient’s quality of life.

  • 2023
    Selected as 'Pohang Promising Small Giants'
    Awarded with 'Industry-academia collaboration R&D' project' by the Ministry of SMEs and startups
    Patent registration in China for TCB2 (SLC-3010)
    Awarded with 'Startup Leap Package' by the Ministry of SMEs and startups
  • 2022
    IND approval from MFDS for phase I/2 clinical trial
    Acquisition of ‘AA grade’ from Innobiz, a certificate for innovative biotech
    IND approval from US FDA for phase I/2a clinical trial
    Attraction of USD 27M from Series B Financing
    PCT and priority application for predictive CDx patent (SLC-1010)
    Patent registration in Japan and Canada for TCB2 (SLC-3010)
  • 2021
    TCB2 patent registration (USA, Australia, Russia, SLC-3010)
    Publication of SLC-3010 at OncoImmunology (Crystal structure of human interleukin-2 in complex with TCB2, a new antibody-drug candidate with antitumor activity)
    Presentation at American Association for Cancer Research (AACR) 2021
  • 2020
    Attraction of USD 8 million Bridge funding
    Awarded Minister of SMEs and startup prize: a venture foundation promotion for merit program
    TCB2 patent registration (Korea, SLC-3010)
    Attraction of USD 12 million Series A
    Awarded with an ‘Development of fundamental technology of small and medium business foundation' by the Ministry of SMEs and startups
  • 2019
    Publication of SLC-3010 at OncoImmunology (TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity)
    Registration of corporate affiliated research center
    Introduction of TCB2 technology from Institute for Basic Science
    Establishment of the Seoul Research center (Munjeong-dong, Songpa-gu)
    Attraction of USD 2.6 million Pre-series A
    CDMO contract with GenScript for immuno-anticancer drug
  • 2018
    Awarded with an ‘innovative technology support project’ by the Ministry of SMEs and startups
    Foundation of Selecxine Inc.

Leadership

Selecxine is working with members who are experts in the pharmaceutical
development field and talented individuals with expertise in the relevant field to
achieve the goal of pioneering innovative immunotherapeutics.

go top